Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 32
1.
BMJ Case Rep ; 17(5)2024 May 03.
Article En | MEDLINE | ID: mdl-38702071

We describe an early adolescent male who was diagnosed with vascular malformation associated with unilateral limb overgrowth based on the clinical findings of a persistent port-wine stain since birth and gradually progressing right lower limb oedema since early childhood. Clinicians should keep in mind to clinically evaluate such malformations in detail, as well as contemplate genetic testing in patients presenting with a large port-wine stain at birth, particularly if well demarcated and lateral in a lower extremity.


Edema , Lower Extremity , Port-Wine Stain , Humans , Male , Adolescent , Edema/etiology , Port-Wine Stain/diagnosis
2.
Pediatr Rev ; 44(8): 477-480, 2023 Aug 01.
Article En | MEDLINE | ID: mdl-37525304
3.
BMJ Case Rep ; 15(11)2022 Nov 15.
Article En | MEDLINE | ID: mdl-36379634

Congenital lobar emphysema (CLE)/congenital alveolar overdistension/congenital lobar overinflation or infantile lobar emphysema is a rare developmental anomaly of the lower respiratory tract which is characterised by hyperinflation of one or more of the pulmonary lobes. Histopathology may be variable, which may show abnormality in the cartilage, granulation tissue, mucosal folds, etc. We report a rare underlying histopathology in a preterm neonate with CLE. This entity referred to as pulmonary interstitial glycogenosis (PIG) is a group of heterogeneous lung disease affecting the lung parenchyma and is characterised by the presence of glycogen laden cells in the lung interstitium. This impairs the gas exchange and typically manifest as tachypnoea, retractions, hypoxia and increased respiratory support. Our case report highlights the association of CLE and PIG and a review of literature. One should always have a detailed histopathology in children presenting with CLE to rule out PIG.


Emphysema , Glycogen Storage Disease , Lung Diseases, Interstitial , Pulmonary Emphysema , Humans , Pulmonary Emphysema/complications , Pulmonary Emphysema/diagnostic imaging , Pulmonary Emphysema/congenital , Lung Diseases, Interstitial/complications , Lung Diseases, Interstitial/diagnostic imaging , Lung Diseases, Interstitial/pathology , Lung/pathology , Glycogen Storage Disease/complications , Glycogen Storage Disease/diagnosis , Glycogen Storage Disease/pathology
4.
Adv Chronic Kidney Dis ; 29(3): 251-262, 2022 05.
Article En | MEDLINE | ID: mdl-36084972

Adolescent obesity and CKD are both significant public health issues independently. When seen as comorbid conditions, they can cause deleterious health outcomes that put them on the fast track to necessitate dialysis or transplantation. This paper analyzes the effects of various biomarkers and comorbidities seen in the intersection of obesity and CKD in the adolescent population. We illustrate the estimated prevalence of these biomarkers and comorbidities through a review of the literature, available treatment, and obesity-related glomerulopathies. We found significant prevalence of the biomarkers, microalbuminuria (9.42% ± 9.31% and interquartile range [IQR] of 9.5%), hypertension (23.60% ± 22.5% and IQR of 9.5%), low high-density lipoprotein (14.34% ± 5.46% and IQR of 5%), hyperfiltration (3.12% ± 5.16% and IQR of 4%), and lower estimated glomerular filtration rate 4.59 ± 2.75 and IQR of 3%. Identification of prevalent biomarkers and their manifestations can serve to inform clinicians what to look for in daily setting and help elucidate the magnitude of this growing issue. Additionally, pertinent treatment options from pharmacotherapy to bariatric surgery are outlined to provide care providers with the full spectrum of treatment options for obesity in adolescent populations.


Pediatric Obesity , Renal Insufficiency, Chronic , Adolescent , Comorbidity , Glomerular Filtration Rate , Humans , Pediatric Obesity/epidemiology , Prevalence , Renal Insufficiency, Chronic/epidemiology , Renal Insufficiency, Chronic/therapy
5.
BMJ Case Rep ; 14(4)2021 Apr 07.
Article En | MEDLINE | ID: mdl-33827885

The current case report describes a 13-year-old young boy who presented with purpuric rashes following a completely asymptomatic COVID-19 infection and biopsy-confirmed leucocytoclastic vasculitis, mild haematuria and mild elevation of serum IgA. This case highlights one of the dermatological manifestations of COVID-19 infection which has not been reported so far. Paediatricians should explore the history of this infection when evaluating any child presenting with a vasculitic rash.


COVID-19/complications , Vasculitis, Leukocytoclastic, Cutaneous/diagnosis , Adolescent , Asymptomatic Infections , Humans , Immunoglobulin A/blood , Male , Purpura , Vasculitis, Leukocytoclastic, Cutaneous/virology
6.
BMJ Case Rep ; 13(12)2020 Dec 21.
Article En | MEDLINE | ID: mdl-33370939

Slowly progressing unilateral upper limb weakness in a previously healthy child can occur due to number of causes which requires a thorough history, physical examination followed by radiological examination, electromyography and so on. Among the various aetiologies, a rare condition such as Hirayama disease is one of the differentials to be considered. There has been a wealth of literature reported on this disease and our case is a learning lesson for all paediatricians to be aware of Hirayama disease and its current concepts.


Braces , Muscle Weakness/etiology , Spinal Cord/pathology , Spinal Muscular Atrophies of Childhood/diagnosis , Adolescent , Cervical Vertebrae/diagnostic imaging , Diagnosis, Differential , Electromyography , Humans , Magnetic Resonance Imaging , Male , Muscle Weakness/diagnosis , Muscle Weakness/therapy , Muscle, Skeletal/innervation , Muscle, Skeletal/physiopathology , Neck , Spinal Cord/diagnostic imaging , Spinal Muscular Atrophies of Childhood/complications , Spinal Muscular Atrophies of Childhood/therapy , Upper Extremity/innervation
9.
BMJ Case Rep ; 13(9)2020 Sep 02.
Article En | MEDLINE | ID: mdl-32878857
10.
Saudi J Kidney Dis Transpl ; 31(2): 553-555, 2020.
Article En | MEDLINE | ID: mdl-32394935

Kidney transplant recipients frequently suffer from skin infections and malignancies. New dermatosis can appear after transplantation. Although children are maintained on varying degrees of chronic immunosuppression, there is still a possibility of autoimmune blistering skin conditions, which can pose a diagnostic challenge in terms of clinical presentation. Histopathology of skin lesions is very important which helps in correct diagnosis and prompt treatment. We report an extremely rare case of linear IgA dermatosis in a child who was postrenal transplant and treated successfully with dapsone and steroids.


Kidney Transplantation/adverse effects , Linear IgA Bullous Dermatosis/immunology , Adolescent , Dapsone/therapeutic use , Dermatologic Agents/therapeutic use , Humans , Linear IgA Bullous Dermatosis/diagnosis , Linear IgA Bullous Dermatosis/drug therapy , Male , Steroids , Treatment Outcome
11.
Kidney Int ; 97(6): 1260-1274, 2020 06.
Article En | MEDLINE | ID: mdl-32386968

Recessive mutations in diacylglycerol kinase epsilon (DGKE) display genetic pleiotropy, with pathological features reported as either thrombotic microangiopathy or membranoproliferative glomerulonephritis (MPGN), and clinical features of atypical hemolytic uremic syndrome (aHUS), nephrotic syndrome or both. Pathophysiological mechanisms and optimal management strategies have not yet been defined. In prospective and retrospective studies of aHUS referred to the United Kingdom National aHUS service and prospective studies of MPGN referred to the National Registry of Rare Kidney Diseases for MPGN we defined the incidence of DGKE aHUS as 0.009/million/year and so-called DGKE MPGN as 0.006/million/year, giving a combined incidence of 0.015/million/year. Here, we describe a cohort of sixteen individuals with DGKE nephropathy. One presented with isolated nephrotic syndrome. Analysis of pathological features reveals that DGKE mutations give an MPGN-like appearance to different extents, with but more often without changes in arterioles or arteries. In 15 patients presenting with aHUS, ten had concurrent substantial proteinuria. Identified triggering events were rare but coexistent developmental disorders were seen in six. Nine with aHUS experienced at least one relapse, although in only one did a relapse of aHUS occur after age five years. Persistent proteinuria was seen in the majority of cases. Only two individuals have reached end stage renal disease, 20 years after the initial presentation, and in one, renal transplantation was successfully undertaken without relapse. Six individuals received eculizumab. Relapses on treatment occurred in one individual. In four individuals eculizumab was withdrawn, with one spontaneously resolving aHUS relapse occurring. Thus we suggest that DGKE-mediated aHUS is eculizumab non-responsive and that in individuals who currently receive eculizumab therapy it can be safely withdrawn. This has important patient safety and economic implications.


Atypical Hemolytic Uremic Syndrome , Diacylglycerol Kinase , Atypical Hemolytic Uremic Syndrome/drug therapy , Atypical Hemolytic Uremic Syndrome/epidemiology , Atypical Hemolytic Uremic Syndrome/genetics , Child, Preschool , Diacylglycerol Kinase/genetics , Humans , Prospective Studies , Retrospective Studies , United Kingdom
12.
Arch Dis Child Educ Pract Ed ; 105(2): 97-98, 2020 04.
Article En | MEDLINE | ID: mdl-30442674

Differentiated thyroid cancer is a rare disease in children and adolescents and manifests exclusively in the form of papillary thyroid cancer (PTC). We present a rare case of PTC who presented initially with lung symptoms and miliary nodules on chest X-ray. This case emphasises the important differential of miliary mottling of the lungs.


Lung Neoplasms/diagnostic imaging , Lung Neoplasms/secondary , Thyroid Cancer, Papillary/secondary , Thyroid Neoplasms/pathology , Child , Female , Humans , Lung Neoplasms/therapy , Radiography, Thoracic , Thyroid Cancer, Papillary/diagnostic imaging , Thyroid Cancer, Papillary/therapy , Thyroid Neoplasms/diagnostic imaging , Thyroid Neoplasms/therapy
16.
Pediatr Transplant ; 23(7): e13566, 2019 11.
Article En | MEDLINE | ID: mdl-31407858

Renal transplantation is the treatment of choice for ESRD in children. It is associated with better quality of life, growth of children, and improved long-term survival. The aim of the study was to evaluate the outcomes of pediatric renal transplantation at a tertiary care center in UAE. A retrospective chart review was undertaken for all the pediatric renal transplants performed at Sheikh Khalifa Medical City, Abu Dhabi, UAE, over the past 9 years. The study evaluated the demographic data, outcomes, and complications of pediatric renal transplantation. The post-transplantation outcomes including surgical complications, documented infections, graft rejection, graft and patient survival, effect on growth, and eGFR were reviewed. Between 2010 and 2018, 30 pediatric patients underwent renal transplantation. The follow-up period ranged from 1 to 9 years with a mean of 3.3 years. The mean age of the patients at the time of transplant was 9.8 years, and 56.7% were males. Prior to the transplantation, the majority of the recipients were on peritoneal dialysis (70.0%). Main source of renal donation at our center was from LRD, chiefly from parents. Patient survival at 1 and 5 years was 100% and 96.7%, respectively. Graft survival at 1 and 5 years was 96.7% and 83.3%, respectively. During the 9-year follow-up period, 5 (16.7%) recipients experienced rejection episode. This study demonstrates that during 5-year period, pediatric kidney transplantation program has achieved optimal patient (96.7%) and graft (83.3%) survival rates and is comparable to well-established centers.


Kidney Failure, Chronic/surgery , Kidney Transplantation , Adolescent , Child , Child, Preschool , Female , Glomerular Filtration Rate , Graft Rejection , Graft Survival , Humans , Living Donors , Male , Program Development , Quality of Life , Retrospective Studies , Treatment Outcome , United Arab Emirates/epidemiology
17.
J Paediatr Child Health ; 55(10): 1237-1240, 2019 10.
Article En | MEDLINE | ID: mdl-30714243

AIM: Atypical haemolytic uraemic syndrome (aHUS) is a debilitating condition that can cause significant morbidity and mortality in children if not adequately and promptly treated. This report shares real-world data on the use of eculizumab in children with aHUS. METHODS: We report our experience with the use of eculizumab in 14 children with aHUS. RESULTS: The median age at aHUS diagnosis was 12 months (range: 2-108 months), with six (42.9%) patients presenting in infancy and six (42.9%) being males. Eculizumab therapy was associated with haematological and thrombotic microangiopathy responses in 14 (100%) and 13 (92.9%) patients after a median of 9 days (range: 7-12 days) and 9.5 days (range: 7-14 days), respectively. None of the six patients who were previously treated with plasma therapy required any further infusions. Of the six patients who previously required dialysis, only one patient continued to do so and eventually received a renal transplant. The median time to ≥25% decrease in serum creatinine level in the remaining patients was 16 days (range: 14-21 days), and estimated glomerular filtration rate increased from a median of 17-101 mL/min/1.73 m2 . The safety profile was similar to that reported in the literature, and 10 patients continue to receive therapy, with 3 being on the drug for 4 or more years. CONCLUSION: Our study adds to the growing body of evidence highlighting the efficacy and safety of eculizumab for the management of children with aHUS.


Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/pharmacology , Atypical Hemolytic Uremic Syndrome/drug therapy , Complement Inactivating Agents/administration & dosage , Complement Inactivating Agents/pharmacology , Outcome Assessment, Health Care , Child , Child, Preschool , Female , Humans , Infant , Male , United Arab Emirates
18.
CEN Case Rep ; 8(3): 173-177, 2019 08.
Article En | MEDLINE | ID: mdl-30747351

Metabolic disorders, although rare, can involve multiple organ systems and have a varied presentation. Renal involvement has been reported in several metabolic disorders in the pediatric age group. We report a rare metabolic disorder, long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, in a child who developed steroid-resistant nephrotic syndrome at the age of 5 years. Renal biopsy showed features of collapsing glomerulopathy. The child had progressive chronic kidney disease. Alternative immunosuppressants including tacrolimus failed to show any clinical improvement. There have been no reports of children with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency developing steroid-resistant nephrotic syndrome and collapsing glomerulopathy. This case highlights the need to monitor renal function and proteinuria among this group of children.


Cardiomyopathies/complications , Kidney Diseases/etiology , Kidney Glomerulus/pathology , Lipid Metabolism, Inborn Errors/complications , Mitochondrial Myopathies/complications , Mitochondrial Trifunctional Protein/deficiency , Nervous System Diseases/complications , Rhabdomyolysis/complications , Child, Preschool , Humans , Kidney Diseases/pathology , Male
20.
Saudi J Kidney Dis Transpl ; 29(5): 1203-1206, 2018.
Article En | MEDLINE | ID: mdl-30381520

The incidence of urolithiasis in children has shown an increase in recent years which may be attributed to changing dietary patterns, sedentary lifestyles, and obesity. Among the various etiologies for renal stones in children, two rare entities worth mentioning are cystinuria and 2, 8-dihydroxyadenine (DHA) urolithiasis. Cystinuria is an inherited cause of nephrolithiasis which occurs due to impaired cystine reabsorption in the renal proximal tubule. 2, 8-DHA urolithiasis is an inherited autosomal recessive disease resulting in urinary stone disease secondary to deficiency of adenine phosphoribosyltransferase (APRT) activity. We describe two children who presented to our clinic with these two rare causes of stones.


Adenine Phosphoribosyltransferase/deficiency , Cystinuria/complications , Kidney Calculi/etiology , Metabolism, Inborn Errors/complications , Urolithiasis/complications , Adenine Phosphoribosyltransferase/genetics , Allopurinol/therapeutic use , Child, Preschool , Citric Acid/therapeutic use , Cystinuria/diagnosis , Cystinuria/genetics , Enzyme Inhibitors/therapeutic use , Genetic Predisposition to Disease , Humans , Kidney Calculi/diagnosis , Kidney Calculi/therapy , Lithotripsy , Male , Metabolism, Inborn Errors/diagnosis , Metabolism, Inborn Errors/genetics , Phenotype , Stents , Treatment Outcome , Urolithiasis/diagnosis , Urolithiasis/genetics
...